JPRN-jRCT2080220235未知3 期
SPP100 (Aliskiren) regimen in hypertensive patients with renal dysfunction
ovartis Pharma K.K.0 个研究点目标入组 38 人开始时间: 2006年4月21日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Inclusion criteria
- •- Age: 20-80 years old
- •- Gender: Male or female
- •- Status: Outpatients
- •- Elevated Serum Creatinine
- •Exclusion criteria
- •- Patients suspected of malignant hypertension
- •- Patients with a clinically significant allergy
- •- Patients who have received other investigational drug
- •Other protocol-defined inclusion/exclusion criteria may apply
排除标准
- 未提供
研究者
相似试验
已完成
3 期
SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal DysfunctionHypertensionNCT00299832Novartis40
已完成
3 期
SPP100 (Aliskiren) Regimen in Patients With Severe HypertensionHypertensionNCT00299806Novartis39
招募中
不适用
Efficacy of Aliskiren in hypertensive patients with diabetes mellitus or obesityEssential hypertensive patients with type II diabetes or obesityJPRN-UMIN000011865Tokyo Women's Medical University104
未知
Unknown
Clinical study using spironolactone for hypertensive patients with type 2 diabetes and albuminuriaType 2 DiabetesJPRN-jRCT1080222094Tohoku University140
已完成
2 期
SPP100 Dose Finding Study in JapanHypertensionNCT00311012Novartis445